PRAGUE-8 PRAGUE-8 ESC 2007.

JPAD The Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes Trial. Efficacy of Low-Dose Aspirin Therapy for the Primary Prevention.
DIPOM* Prévention par ß-bloquants d’évènements graves après chirurgie non cardiaque chez le diabétique AHA 2004 (*) Diabetic Postoperative Mortality and.
FUTURA/OASIS-8 Low versus standard dose unfractionned heparin for percutaneous coronary intervention in acute coronary syndrome patients treated with fondaparinux.
FINESSE Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events ESC 2007 FINESSE.
ATOLL Acute STEMI treated with primary PCI and intravenous enoxaparin or UFH to lower ischemic and bleeding events at short and long-term follow-up. Montalescot.
ABOARD* Essai multicentrique randomisé comparant une stratégie invasive immédiate versus différée chez des patients présentant un syndrome coronarien aigu.
PEACE* Prévention par un IEC** (trandolapril) des accidents évolutifs graves chez des coronariens stables à fonction systolique ventriculaire gauche conservée.
ATLAS ACS 2 -TIMI 51 Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome.  Présentée.
TITRATION DU CLOPIDOGREL Tailored Clopidogrel Loading Dose according to Platelet Reactivity Monitoring Decrease Early Stent Thrombosis. Paganelli F et.
Apixaban versus warfarin in patients with atrial fibrillation
SYNTAX The synergy between percutaneous coronary intervention with TAXUS and cardiac surgery. Primary endpoint results at one year in the randomized cohort.
RE-LY Randomization Evaluation of Long-Term Anticoagulation Therapy Connolly S.J et al. N Engl J Med 2009 ; 361.
TRITON-TIMI 38 Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes.
EXPLORE-Xa Betrixaban Compared With Open‑Label Dose-Adjusted Warfarin in Patients With Non-Valvular Atrial Fibrillation. Ezekowitz MD et al. ACC 2010.
EINSTEIN-DVT Oral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. Büller H et al. ESC 2010.
TRA-CER Vorapaxar, a platelet thrombin receptor antagonist, in acute coronary syndromes. Mahaffey KW et al . AHA 2011.
ISAR REACT 3A A trial of reduced dose of unfractioned heparin in biomarker negative patients undergoing percutaneous coronary intervention. Schulz S et.
un infarctus du myocarde récent.
TRIANA Tratamiento del infarto agudo de miocardio en ancianos Bueno H et al.
Platelet inhibition with cangrelor in patients undergoing PCI.
PRODIGY Prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia study Valgimigli M et al. ESC 2011.
ROCKET AF Rivaroxaban Once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in Atrial.
Critère principal : décès CV, IDM ou AVC n = Médiane de suivi 33 mois
TRITON-TIMI 38 Evaluation of Prasugrel Compared with Clopidogrel in Patients with Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention:
Étude TOTAL : thrombo-aspiration lors de l’angioplastie primaire (2)
PRAGUE 7 Primary angioplasty in patients from general hospital transported to cathlab units with/without emergency thrombolysis Widimski P et al.
Intravenous platelet blockade with cangrelor during PCI.
PENTHIFRA PLUS Influence of the duration of fondaparinux prophylaxis in preventing venous thromboembolism following hip fracture. Bauer KA et al. Blood.
TRITON-TIMI 38 Trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infraction.
AIDA STEMI The abciximab intracoronary versus intravenously drug application in ST-elevation myocardial infarction (AIDA STEMI). Thiele H et al. AHA 2011.
ISAR-REACT 4 The abciximab intracoronary versus intravenously drug application in ST-elevation myocardial infarction (AIDA STEMI). Kastrati A et al. AHA.
SPORTIF V Comparaison de deux anticoagulants oraux,
Christine Rubio-Sapède
MM-WES Effect of Genotyping Warfarin Patients on Outcomes: Results from The National Community-based Medco-Mayo Warfarin Effectiveness Study. Epstein RS.
RE-COVER Dabigatran versus warfarine dans le traitement d’un accident thrombo-embolique veineux Schulman S et al. N Engl J Med 2009 ;361: Dabigatran.
CLOTS 1 Efficacité des bas de contention dans la prévention des thromboses veineuses profondes après un AVC (essai CLOTS 1) : étude multicentrique randomisée.
ROCKET AF Rivaroxaban versus warfarine dans la fibrillation atriale non valvulaire Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. Patel.
CRASH-2 Effets de l’acide tranexamique sur la mortalité, les événements cardiovasculaires et la transfusion sanguine chez les patients traumatisés ayant.
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack CHANCE Wang Y et al. N Engl J Med 2013 ;369:11-19.
WOMEN’s HEALTH STUDY (WHS) Effet de l’aspirine à faible dose pour la prévention du thromboembolisme veineux. Essai randomisé. Glynn RJ et al. Ann Intern.
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban once daily, oral,
CHARISMA Analyse post-hoc Complications hémorragiques de l’association clopidogrel + aspirine chez les patients avec maladie vasculaire stable ou avec.
Apixaban for Extended Treatment of Venous Thromboembolism Agnelli G, et al. N Engl J Med 2012 DOI : /NEJMoa AMPLIFY-EXT.
ESPRIT Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT) : randomised controlled trial The ESPRIT Study.
PROTECT AF Fermeture percutanée de l’auricule gauche versus warfarine en prévention des AVC chez des patients en fibrillation auriculaire : étude randomisée.
Quantification du biais d’estimation Par méta-analyse exemple avec les nouveaux anticoagulants oraux dans la fibrillation atriale Jean-Christophe Lega.
DIRECT STUDY Thromboprophylaxie par HBPM (daltéparine) chez les patients en réanimation pour insuffisance rénale sévère Prophylaxis against deep vein thrombosis.
PRAGUE-14 Perioperative cardiovascular complications versus perioperative bleeding in patients with cardiovascular complications undergoing non- cardiac.
LODOCO Low Dose Colchicine for Secondary Prevention of Cardiovascular Disease Nidorf M et al. AHA 2012.
ECASS III Thrombolyse avec l’altéplase 3 à 4,5 heures après un AVC ischémique. Hacke et al. N Engl J Med 2008;359: Thrombolysis with alteplase.
Cerebrovascular events in patients with atrial fibrillation randomized to edoxaban versus warfarin : effective anticoagulation with factor Xa next.
L’influence de la fibrillation atriale sur les caractéristiques échocardiographiques de la sténose aortique Dr. F.HALOUI, Dr. K.KHARBOUCHE Pr. R.HABBAL.
FREEDOM Strategies for Multivessel Revascularization in Patients with Diabetes N Engl J Med 2012 DOI : /NEJMoa Farkouh ME et al. AHA 2012.
Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS TIMI 51 ATLAS ACS 2 –TIMI 51 * Gibson CM.
RE-LY Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial.
Oral rivaroxaban for symptomatic venous thromboembolism
Low-Molecular-Weight Heparin and Mortality in Acutely Ill Medical Patients. LIFENOX Kakkar A.K, et al. N Engl J Med 2011 ; 365 :
ENGAGE-AF TIMI 48 Edoxaban versus warfarin in patients with atrial fibrillation. AHA 2013 Giugliano R.P, et al. N Engl J Med 2013 ; 369 :
REGISTRE IMPROVE Prophylaxie de la maladie thrombo-embolique veineuse (MTEV) chez des patients hospitalisés pour une pathologie aiguë en service de médecine.
CHARISMA Clopidogrel + aspirine contre aspirine seule pour la prévention des accidents athérothrombotiques. Bhatt DL et al. N Engl J Med 2006;354:
Aspirin in Patients Undergoing Non Cardiac Surgery POISE 2 Devereaux PJ et al. NEJM 2014;370:
ADVANCE-2 Apixaban versus énoxaparine pour la thromboprophylaxie après prothèse totale du genou (ADVANCE-2): un essai randomisé en double-aveugle Lassen.
ARISTOTLE Apixaban versus warfarine dans la fibrillation atriale
PRoFESS Aspirine et dipyridamole à libération prolongée versus clopidogrel en prévention des récidives d’AVC : étude en double aveugle contrôlée par placebo.
POISE-2 Aspirin in patients undergoing noncardiac surgery ACC Devereaux P.J, et al. N Engl J Med 2014 ; 370 :
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism HOKUSAI-VTE Büller HR et al. N Engl J Med 2013 ; 369 :
ACTIVE A Prévention des événements de la fibrillation auriculaire par le clopidogrel Effect of Clopidogrel added to Aspirin in patients with Atrial Fibrillation.
JPPP Low-dose aspirin for primary prevention of cardiovascular events in elderly patients with multiple atherosclerotic risk factors. A randomized control.
TRA 2° P Vorapaxar in the secondary prevention in atherothrombotic events Morrow DA et al. N Engl J Med 2012 ; 366 : Morrow DA et al. ACC 2012.